RCMI Coordinating Center (RCMI CC) Header Logo

Connection

José F. Rodríguez-Orengo to Drug Therapy, Combination

Back to Details
This is a "connection" page, showing publications José F. Rodríguez-Orengo has written about Drug Therapy, Combination.
José F. Rodríguez-Orengo
Connection Strength
0.238
Drug Therapy, Combination
  1. Rodr?guez-Torres M, Burguera J, Hallman D, Rodr?guez-Orengo J, Echeandia M. ?Hepatitis C viral kinetics in Latino patients: a comparison to African American and Caucasian patients. Ann Hepatol. 2012 Jul-Aug; 11(4):450-63.
    View in: PubMed
    Score: 0.104
  2. Rodr?guez-Torres M, Rodr?guez-Orengo JF, R?os-Bedoya CF, Fern?ndez-Carbia A, Gonz?lez-Lassalle E, Salgado-Mercado R, Marxuach-Cu?tara AM. Efficacy and safety of peg-IFN alfa-2a with ribavirin for the treatment of HCV/HIV coinfected patients who failed previous IFN based therapy. J Clin Virol. 2007 Jan; 38(1):32-8.
    View in: PubMed
    Score: 0.070
  3. Rodr?guez-Torres M, Salgado-Mercado R, R?os-Bedoya CF, Aponte-Rivera E, Marxuach-Cu?tara AM, Rodr?guez-Orengo JF, Fern?ndez-Carbia A. High eradication rates of Helicobacter pylori infection with first- and second-line combination of esomeprazole, tetracycline, and metronidazole in patients allergic to penicillin. Dig Dis Sci. 2005 Apr; 50(4):634-9.
    View in: PubMed
    Score: 0.063
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

For technical support please contact support